Interpace Biosciences, Inc.

OTCPK:IDXG Stok Raporu

Piyasa değeri: US$10.8m

Interpace Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Interpace Biosciences has been growing earnings at an average annual rate of 50.7%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 9.7% per year.

Anahtar bilgiler

50.7%

Kazanç büyüme oranı

52.7%

EPS büyüme oranı

Healthcare Sektör Büyümesi8.5%
Gelir büyüme oranı9.7%
Özkaynak getirisin/a
Net Marj7.2%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

Gelir ve Gider Dağılımı

Interpace Biosciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OTCPK:IDXG Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24423191
31 Mar 24411201
31 Dec 23401201
30 Sep 2338-1191
30 Jun 2337-2201
31 Mar 2334-4201
31 Dec 2232-6201
30 Sep 2233-6211
30 Jun 2232-6211
31 Mar 2231-4201
31 Dec 2133-7201
30 Sep 2134-13222
30 Jun 2134-18242
31 Mar 2133-24253
31 Dec 2032-29273
30 Sep 2027-32273
30 Jun 2026-33283
31 Mar 2027-33283
31 Dec 1924-27253
30 Sep 1926-20233
30 Jun 1924-16192
31 Mar 1923-12182
31 Dec 1822-12172
30 Sep 1820-13182
30 Jun 1819-13182
31 Mar 1817-18172
31 Dec 1716-13171
30 Sep 1715-1152
30 Jun 1714-5152
31 Mar 1714-3162
31 Dec 1613-8162
30 Sep 1613-23192
30 Jun 1612-23202
31 Mar 1610-28232
31 Dec 159-31252
30 Sep 15-83-31132
30 Jun 15-57-27151
31 Mar 15-28-20150
31 Dec 141-13150
30 Sep 14123-6230
30 Jun 14129-5230
31 Mar 14135-4240
31 Dec 13147-2250

Kaliteli Kazançlar: IDXG has high quality earnings.

Büyüyen Kar Marjı: IDXG became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IDXG has become profitable over the past 5 years, growing earnings by 50.7% per year.

Büyüme Hızlandırma: IDXG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: IDXG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (11.4%).


Özkaynak Getirisi

Yüksek ROE: IDXG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin